Hélène Théophile1, Nicholas Moore2,3,4, Philip Robinson5,6, Bernard Bégaud2,3,4, Antoine Pariente2,3,4. 1. Département de Pharmacologie médicale, Centre Régional de Pharmacovigilance, CHU Bordeaux, Hôpital Pellegrin-Bât. 1A Zone Nord, 33076, Bordeaux Cedex, France. helene.theophile@u-bordeaux.fr. 2. Département de Pharmacologie médicale, Centre Régional de Pharmacovigilance, CHU Bordeaux, Hôpital Pellegrin-Bât. 1A Zone Nord, 33076, Bordeaux Cedex, France. 3. INSERM CR 1219, 146 rue Léo Saignat, Case 121, 33076, Bordeaux Cedex, France. 4. University of Bordeaux, 146 rue Léo Saignat, Case 36, 33076, Bordeaux Cedex, France. 5. CIC Bordeaux CIC1401, Bordeaux, France. 6. ADERA, Pessac, France.
Abstract
INTRODUCTION: The case-population approach compares exposure among cases to that of their source population. By using aggregated data to estimate the denominator, this approach can provide a real-time estimate of an association that could be particularly valuable to explore urgent vaccine safety concerns and to generate signals during a vaccine campaign. OBJECTIVE: Our objective was to present the vaccine case-population method, a method derived from the case-population approach and adapted for vaccine safety surveillance, and to test it using several published examples. METHODS: For the vaccine case-population method, exposure in the population is estimated from the sum of at-risk periods using the number of vaccinated individuals, or data of vaccine sales, and the at-risk period considered for the vaccine-event pair. The vaccine case-population method was applied to data from published case-control studies retrieved from the MEDLINE database and having quantified risks associated with vaccines. Odds ratios derived from the vaccine case-population method were compared with those from published case-control studies. RESULTS: A total of 20 vaccine-event pairs were retrieved in which the vaccine case-population method could be applied. For all identified vaccine-event pairs, when a significant association was found using the vaccine case-population method, a significant association was also found in the corresponding case-control study. Conversely, when no association was found by the vaccine case-population method, no association was found in the corresponding case-control study. CONCLUSION: These results suggest that the vaccine case-population method can produce coherent conclusions and may be used in the future for prospective investigation of urgent vaccine safety concerns or for the prospective generation of vaccine safety signals. This method could also be used to identify selection bias from cases excluded from the case-control study.
INTRODUCTION: The case-population approach compares exposure among cases to that of their source population. By using aggregated data to estimate the denominator, this approach can provide a real-time estimate of an association that could be particularly valuable to explore urgent vaccine safety concerns and to generate signals during a vaccine campaign. OBJECTIVE: Our objective was to present the vaccine case-population method, a method derived from the case-population approach and adapted for vaccine safety surveillance, and to test it using several published examples. METHODS: For the vaccine case-population method, exposure in the population is estimated from the sum of at-risk periods using the number of vaccinated individuals, or data of vaccine sales, and the at-risk period considered for the vaccine-event pair. The vaccine case-population method was applied to data from published case-control studies retrieved from the MEDLINE database and having quantified risks associated with vaccines. Odds ratios derived from the vaccine case-population method were compared with those from published case-control studies. RESULTS: A total of 20 vaccine-event pairs were retrieved in which the vaccine case-population method could be applied. For all identified vaccine-event pairs, when a significant association was found using the vaccine case-population method, a significant association was also found in the corresponding case-control study. Conversely, when no association was found by the vaccine case-population method, no association was found in the corresponding case-control study. CONCLUSION: These results suggest that the vaccine case-population method can produce coherent conclusions and may be used in the future for prospective investigation of urgent vaccine safety concerns or for the prospective generation of vaccine safety signals. This method could also be used to identify selection bias from cases excluded from the case-control study.
Authors: T V Murphy; P M Gargiullo; M S Massoudi; D B Nelson; A O Jumaan; C A Okoro; L R Zanardi; S Setia; E Fair; C W LeBaron; M Wharton; J R Livengood; J R Livingood Journal: N Engl J Med Date: 2001-02-22 Impact factor: 91.245
Authors: James Baggs; Julianne Gee; Edwin Lewis; Gabrielle Fowler; Patti Benson; Tracy Lieu; Allison Naleway; Nicola P Klein; Roger Baxter; Edward Belongia; Jason Glanz; Simon J Hambidge; Steven J Jacobsen; Lisa Jackson; Jim Nordin; Eric Weintraub Journal: Pediatrics Date: 2011-04-18 Impact factor: 7.124
Authors: M M van der Klauw; B H Stricker; R M Herings; W S Cost; H A Valkenburg; J H Wilson Journal: Br J Clin Pharmacol Date: 1993-04 Impact factor: 4.335